We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
84.00 | 0.75% | 11,352.00 | 11,350.00 | 11,352.00 | 11,412.00 | 11,288.00 | 11,288.00 | 3,579,740 | 16:29:59 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 29.55 | 175.98B |
Date | Subject | Author | Discuss |
---|---|---|---|
23/11/2020 09:02 | To be fair to BBC - they are taking that from the AZN press release | williamcooper104 | |
23/11/2020 09:01 | Pure speculation on my part, but because of the relatively small number who actually caught Covid (therefore vast majority of sample couldn't be used for measuring efficacy), my suspicion is that the 90% efficacy rate for the better regimen, could be improved upon with more data/larger sample size. They will likely (once emergency approved) roll this out regardless and further optimise dosage as more data come in. | bluemango | |
23/11/2020 08:57 | AZN ran two trials side by side with two different regimens. One regimen showed 90% effectiveness, the other 60%. 70% was the average of the two. The report states: "AstraZeneca continues to engage with governments, multilateral organisations and collaborators around the world to ensure broad and equitable access to the vaccine at no profit for the duration of the pandemic." | daijavu | |
23/11/2020 08:56 | BartyB can you edit your post #3015 please, out by a factor of 10 which is extremely misleading for those not already familiar with the figures. Thank you. | bluemango | |
23/11/2020 08:50 | coxsmn Agree concerning BBC News reporting. I hope they get that sorted ASAP. Should be 90% with 1.5 doses. They should point out all the other positives. The world stock markets should be rocketing on this news. The competitors vaccine announcement had a desired impact,ie stock markets rocketing except competitors, which dropped rapidly, I'm sure that was the desired impact, not the vaccine news, but the impact on competitors. | hyper al | |
23/11/2020 08:43 | BartyB Should that be 70 per cent? | hyper al | |
23/11/2020 08:39 | The AZN vaccine ticks all the boxes. With the right regimen it is 90% effective, it is safer, it is far easier and cheaper to store and distribute than Pfizer's and it is far cheaper to buy than the others too. It has got to be the one the world uses. AZN might make less profit per dose but will sell far more doses. | daijavu | |
23/11/2020 08:29 | OXford top prof on BBC they have the situation where 2 full doses give 70 per cent but a 1/2 dose then a full dose give 90 percent which reduces the amount of vaccine needed | bartyb | |
23/11/2020 08:29 | Then poor reporting by bbc using the 70% as the headline figure, makes our vaccine look the worst so far. Terrible. | coxsmn | |
23/11/2020 08:27 | Prof Pollard saying it's not a competition, and that their vaccine is 'not for profit' (probably why share price is not reacting) But good for its public image. :) The very reason I would rather take it! | hyper al | |
23/11/2020 08:25 | Far better in many ways! | hyper al | |
23/11/2020 08:24 | Even those who did get Covid, not a single person got severe disease, so better than the other two vaccines on that front. | hyper al | |
23/11/2020 08:22 | Now everything makes sense !!! | boxerdogz | |
23/11/2020 08:22 | Prof Pollard talking on BBC News just now | hyper al | |
23/11/2020 08:20 | unastubbs23 Nov '20 - 08:16 - 3004 of 3007 0 1 0 market behaving rationally. what's in this for shares except unquantifiable goodwill? Nailed it | boxerdogz | |
23/11/2020 08:19 | To be fair, it is slightly odd that AZN reported it this way. The trial size was larger for the les effective dose, which may explain why gave it prominence, but it was an experimental treatment. Having done it and established a clear distinction, why not highlight the more effective one instead of just an average that will never apply in reality? | imastu pidgitaswell | |
23/11/2020 08:18 | netc - likely you're right | unastubbs | |
23/11/2020 08:17 | OXB up - so the market is probably impressed but some of the good news probably already factored into AZN price? | netcurtains | |
23/11/2020 08:16 | market behaving rationally. what's in this for shares except unquantifiable goodwill? | unastubbs | |
23/11/2020 08:11 | BBC headline states vaccine is 70% effective, this seems misleading and belittles the achievement if it is actually 90% when administered with a low does followed by a high dose. | coxsmn | |
23/11/2020 08:11 | Mkt looks great across the FTSE. AZN , non for profit ..... | boxerdogz | |
23/11/2020 08:07 | unastubbs Probably getting shorted by their competitors. | hyper al | |
23/11/2020 08:06 | netcurtains American media seems to have moved into the BBC (maybe it has gone into partnership with a USA company), BBC keep talking about things going on in the USA as if we are a state of the USA. Nothing against people in the USA, but I certainly don't want the UK to be part of it! | hyper al |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions